Panel nixes Merck challenge to Sanofi's Nasacort ad claims; Wales MS patients win access to Bayer drug;

> A national panel has nixed a Merck ($MRK) challenge to advertising claims by Sanofi's ($SNY) Chattem over the company's newly launched Nasacort allergy nasal spray. Story

> Multiple sclerosis patients in Wales have won access to Bayer's Sativex. Report

> Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer. Release

> The FDA is seeking a new director for the Center for Drug Evaluation and Research's Office of Medical Policy, which oversees the Office of Prescription Drug Promotion. More

> A judge has side with Depomed in its patent litigation suit against Actavis ($ACT), whose generic of Depomed's Gralise will now be delayed until 2024. Release

> India's Organization of Pharmaceutical Producers of India is asking the Department of Pharmaceuticals to make its Uniform Code of Pharmaceutical Marketing Practices a statutory code. More

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Rapper, actress and producer Queen Latifah—whose mother died of sclerosis-associated lung disease—joined Boehringer's "More than Scleroderma” push.